Dizal Pharmaceutical Co Ltd. Class A

As of June 30, 2026, Dizal Pharmaceutical Co Ltd. Class A carries a market capitalization of 18.57B, placing it among publicly traded companies globally. Its enterprise value stands at 18.19B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Dizal Pharmaceutical Co Ltd. Class A's next confirmed earnings release is scheduled for October 31, 2026.

As of June 30, 2026, Dizal Pharmaceutical Co Ltd. Class A has 465.17M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 19.70, and the price-to-book ratio stands at 16.44.

These figures are as of June 30, 2026. The EV/Sales ratio of 19.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 18.19B versus a market cap of 18.57B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Dizal Pharmaceutical Co Ltd. Class A maintains a current ratio of 2.63, meaning it holds 2.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 120.01, indicating elevated leverage, while an interest coverage ratio of -17.74 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Dizal Pharmaceutical Co Ltd. Class A posted a negative return on equity (ROE) of -100.89, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -24.90, reflecting losses generated across the asset base. The company generates approximately 961,987.22 in revenue per employee across its workforce of 969.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.95 indicates how many times Dizal Pharmaceutical Co Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Dizal Pharmaceutical Co Ltd. Class A recorded 1.97M in income tax expense. The company reported a pretax loss of -581.94M and -579.32M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Dizal Pharmaceutical Co Ltd. Class A's stock has declined approximately 0.60% over the past 52 weeks. The 50-day moving average sits at 58.42, while the 200-day moving average is 54.49.

Over the twelve months ended June 30, 2026, Dizal Pharmaceutical Co Ltd. Class A generated 932.89M in revenue and converted that into -579.32M in net income, yielding earnings per share of -1.27. EBITDA reached -581.34M, while operating income came in at -577.05M.

As of June 30, 2026, Dizal Pharmaceutical Co Ltd. Class A holds 1.74B in cash and equivalents against 1.36B in total debt, resulting in a net debt position of 782.94M. Total book value stands at 1.13B, with working capital of 1.27B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Dizal Pharmaceutical Co Ltd. Class A posted a gross margin of 95.89, reflecting its pricing power and cost economics. The operating margin of -61.86 and net profit margin of -62.10 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Dizal Pharmaceutical Co Ltd. Class A paid dividends of 0.07 per share. The dividend payout ratio of -5.62 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -9.74, meaning Dizal Pharmaceutical Co Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Dizal Pharmaceutical Co Ltd. Class A has an Altman Z-Score of 4.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.